Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma

Cabozantinib is an oral tyrosine-kinase inhibitor whose targets include VEGFR, MET, and AXL. Cabozantinib is approved for the treatment of patients with advanced clear-cell renal-cell carcinoma (RCC) who have received prior antiangiogenic therapy. In the pivotal Phase III trial of second-line RCC, c...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Onco Targets Ther
Main Authors: Gerendash, Benjamin S, Creel, Patricia A
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2017
Fag:
Review
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5656352/
https://ncbi.nlm.nih.gov/pubmed/29089775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S145295
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker